Overview A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19 Status: Recruiting Trial end date: 2022-06-30 Target enrollment: Participant gender: Summary The purpose of this Phase 2 study is to test safety, efficacy, and tolerability of an oral preparation of VB-201 in patients with severe COVID-19 Phase: Phase 2 Details Lead Sponsor: Vascular Biogenics Ltd. operating as VBL Therapeutics